Lupus Foundation of America Greater Ohio Chapter Logo
GREATER OHIO CHAPTER

Toll Free: 1 (888) NO-LUPUS
Phone: (440) 717-0183

Help Us Solve The Cruel MysteryTM

Donate To The Ohio Chapter

Lupus low disease activity state as a realistic treatment goal to improve kidney function and reduce renal relapses for people with Lupus Nephritis

by | Jul 24, 2025

Inside Lupus Research (ILR): Disease Management News

A recent dual-cohort  study has found that Lupus Low Disease Activity State (LLDAS) is an attainable and effective treatment target for people with lupus nephritis (LN, lupus-related kidney disease). LN affects 50-60% of those with systemic lupus erythematosus (SLE) and puts them at  increased risk of disease relapse, renal damage and progression of end-stage-renal disease.

The study consisted of two cohorts of people with LN, the discovery and validation cohort, with 245 individuals diagnosed with LN from 2010 to 2020. The discovery cohort studied 143 subjects, and the validation cohort investigated 102. Researchers looked into subject outcomes at the one-year mark for both cohorts, evaluating whether individuals achieved a complete renal response (CRR), partial renal response (PRR), LLDAS, or met the Definition Of Remission In SLE (DORIS), which is used to measure lupus disease. 

At one year, 49% of participants had achieved LLDAS, while 40% achieved CRR, 10% met PRR and 10% reached DORIS remission. Subjects who achieved CRR, PRR and LLDAS had the lowest risk of relapse and helped preserve long-term kidney function. Results show that LLDAS is an effective and realistic goal to achieve in LN care. It’s also comparable to CRR/PRR, and when combined with renal response measures like these, can help guide treatment strategies and support better long-term health outcomes for people with lupus nephritis.  

Learn more about treating lupus.

Read the study

This post was originally published on this site

Skip to content